Cargando…

The incalculable costs of tuberculosis

Detalles Bibliográficos
Autores principales:	Cox, Helen, Furin, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209750/ https://www.ncbi.nlm.nih.gov/pubmed/34487684 http://dx.doi.org/10.1016/S2214-109X(21)00345-4

Ejemplares similares

Psidium guajava L. An Incalculable but Underexplored Food Crop: Its Phytochemistry, Ethnopharmacology, and Industrial Applications
por: Tousif, Muhammad Imran, et al.
Publicado: (2022)

How COVID-19 could benefit tuberculosis and HIV services in South Africa
por: Keene, Claire, et al.
Publicado: (2020)

Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic
por: Mohr-Holland, Erika, et al.
Publicado: (2021)

Tuberculosis recovery in Georgia: implementing more by 24
por: Kiria, Nana, et al.
Publicado: (2022)

Patient and public involvement in research: the need for budgeting PPI staff costs in funding applications
por: De Simoni, Anna, et al.
Publicado: (2023)

The need to accelerate access to new drugs for multidrug-resistant tuberculosis
por: Cox, Helen S, et al.
Publicado: (2015)

World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis
por: Ntoumi, Francine, et al.
Publicado: (2022)

A threat to decentralised care for drug-resistant tuberculosis
por: Gray, Adam T, et al.
Publicado: (2020)

Promising of Multidrug-resistant Tuberculosis Screening among New Tuberculosis Patients in China
por: Zhang, Hui, et al.
Publicado: (2017)

The disparity between funding for eye research vs. the high cost of sight-loss in the UK
por: Dewing, Jennifer M., et al.
Publicado: (2022)

Understanding spending trends for tuberculosis
por: Zwerling, Alice
Publicado: (2020)

Ferroptosis hijacking by Mycobacterium tuberculosis
por: Gan, Boyi
Publicado: (2023)

The cost of preventable disease in the USA
por: Galea, Sandro, et al.
Publicado: (2020)

Multidrug-resistant tuberculosis in Sierra Leone
por: Lakoh, Sulaiman, et al.
Publicado: (2022)

The importance for tuberculosis of mitigating economic crises
por: Rasella, Davide, et al.
Publicado: (2022)

Tuberculosis control is crucial to achieve the MDGs
por: Atun, Rifat, et al.
Publicado: (2010)

Ending tuberculosis by 2030: understanding the transmission
por: Pandey, Basu Dev, et al.
Publicado: (2023)

CostPlus and implications for generic imatinib
por: Jenei, Kristina, et al.
Publicado: (2022)

The need to prioritise childhood tuberculosis case detection
por: Nkereuwem, Esin, et al.
Publicado: (2021)

Zoonotic tuberculosis in Africa: challenges and ways forward
por: Carruth, Lauren, et al.
Publicado: (2016)

Health-system reforms to control tuberculosis in China
por: Sleigh, Adrian C
Publicado: (2007)

COVID-19 and global childhood tuberculosis notifications
por: Atre, Sachin, et al.
Publicado: (2022)

Costs vs benefits of tackling COVID-19
Publicado: (2020)

Tuberculosis — Reaping benefits from COVID-19 in Portugal
por: Mateiro Gomes, B.L., et al.
Publicado: (2021)

Learning from COVID-19 to reimagine tuberculosis diagnosis
por: Ruhwald, Morten, et al.
Publicado: (2021)

Challenges and opportunities to end tuberculosis in the COVID-19 era
por: Wingfield, Tom, et al.
Publicado: (2021)

Post-tuberculosis sequelae and their socioeconomic consequences: worth investigating
por: Sotgiu, Giovanni, et al.
Publicado: (2021)

Accelerate investment and action to find the missing patients with tuberculosis
por: Dheda, Keertan, et al.
Publicado: (2022)

Tuberculosis and immigration: the challenges in the Latin American and Colombian context
por: López, Darío Sebastián, et al.
Publicado: (2023)

Tackling two pandemics: a plea on World Tuberculosis Day
por: Wingfield, Tom, et al.
Publicado: (2020)

The crucial need for tuberculosis translational research in the time of COVID-19
por: Loh, Fei Kean, et al.
Publicado: (2022)

False-positive COVID-19 results: hidden problems and costs
por: Surkova, Elena, et al.
Publicado: (2020)

The cost and challenge of vaccine development for emerging and emergent infectious diseases
por: Maslow, Joel N
Publicado: (2018)

The potential of polygenic scores to improve cost and efficiency of clinical trials
por: Fahed, Akl C., et al.
Publicado: (2022)

HIV, tuberculosis, and malaria: how can the impact of COVID-19 be minimised?
por: Sands, Peter
Publicado: (2020)

Scaling up tuberculosis preventive therapy for contacts in high transmission settings
por: Majumdar, Suman S, et al.
Publicado: (2020)

Considerations for simultaneous testing of COVID-19 and tuberculosis in high-burden countries
por: Ruhwald, Morten, et al.
Publicado: (2022)

Universal health coverage: an effective intervention for a tuberculosis-free world
por: Pelissari, Daniele Maria, et al.
Publicado: (2022)

Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress?
por: Rangaka, Molebogeng X, et al.
Publicado: (2022)

Replicating research in ecology and evolution: feasibility, incentives, and the cost-benefit conundrum
por: Nakagawa, Shinichi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_elhcbjuuf6ohhmb8j3rt72absf